Even if we are successful in defending against any such claims, any such litigation would likely be protracted, expensive, a distraction to our management team, not viewed favorably by investors and other third parties, and may potentially result in an unfavorable outcome.35Our NeuVax product candidate for which we intend to seek approval as a biological product may face competition sooner than ex